England First to⁢ Offer “Trojan Horse” Drug for Blood Cancer Treatment

Updated June 13,‍ 2025

Thousands of patients in England battling⁢ blood cancer are ⁢set to receive ⁢a groundbreaking “Trojan horse” drug. This innovative treatment, belantamab mafodotin, is designed to⁣ infiltrate ⁤cancer cells and destroy them from within.

The National ‍Institute⁣ for⁤ Health and Care Excellence (Nice) has approved the ⁢drug, offering new hope to those⁢ with multiple myeloma. Belantamab mafodotin can‍ delay the progression of this cancer⁤ three times longer than standard treatments.

administered as an infusion every three weeks alongside other cancer drugs, this targeted therapy is a special antibody that seeks out and binds to cancer cells. The “Trojan‍ horse” moniker comes ‍from its mechanism:⁤ the drug enters the cancer cell and ‍releases a concentrated dose of a lethal molecule,⁤ effectively eliminating the cell from the ‍inside.

NHS England‘s national clinical director for cancer, Peter Johnson, said the new blood cancer treatment would ⁤be life-changing. “Myeloma is an aggressive type of blood cancer, ⁢but we have seen a steady advancement in the outlook for patients over recent ⁤years as we have introduced new targeted therapies,”⁤ Johnson said. “I am delighted that patients in England will⁤ be the first to benefit from this new treatment.”

Approximately⁤ 1,500 patients in England with multiple myeloma, an incurable bone marrow ‍cancer, are expected to benefit each year. The drug, also known⁣ as Blenrep and manufactured by GlaxoSmithKline, will be available to patients whose cancer has advanced or has not responded to initial treatments.

Shelagh McKinlay, director of research and advocacy at Myeloma UK, hailed ⁢the NHS for being the first healthcare ⁣system to implement the new myeloma⁣ treatment.‍ “We have been working very‍ hard for the last year⁣ to get this treatment approved and we certainly know it will transform the lives of thousands of people with myeloma,” mckinlay said.

Paul⁤ Silvester, 60, of Sheffield, experienced remarkable results after being diagnosed with myeloma in 2023. After ⁣his initial treatment failed, ⁢he received belantamab ⁣mafodotin through an ‍early access program at ⁣the royal Hallamshire Hospital.”I feel like this treatment‍ has brought the party balloons back in the house,” Silvester said. “It has been amazing⁤ – within the first two or three weeks, after ⁤the first⁣ dose, I was in remission.”

Clinical trials indicate that belantamab mafodotin,⁤ when combined with bortezomib and dexamethasone, can delay disease⁢ progression by an average ‍of⁢ three years. This is ⁣a significant improvement compared to the one-year delay seen with daratumumab and other treatments.

Helen ⁣Knight,⁣ director of ⁤medicines evaluation at Nice, emphasized the institution’s commitment⁤ to providing timely access to optimal care while ensuring value for ⁢taxpayers. Health Minister⁣ Karin Smyth added, “This groundbreaking therapy puts the NHS at⁣ the forefront ‍of cancer innovation. ⁤By harnessing cutting-edge ‘Trojan horse’ technology, we’re offering new hope⁢ to ⁣blood cancer patients across the country.”

What’s next

With the⁤ rollout of belantamab mafodotin, also known as ⁤Blenrep, England ⁣is poised to lead the way in ⁢innovative cancer care, offering a⁢ potential lifeline to thousands battling multiple myeloma. ⁣Further research and ‍long-term⁤ monitoring will be crucial to fully understand the drug’s impact and ‍optimize its use‍ in treating this challenging disease.